BioAscent

BioAscent is a leading, science-led contract research organization (CRO) specializing in integrated drug discovery services for the pharmaceutical and biotechnology sectors. The company provides an end-to-end platform encompassing assay development, high-throughput screening, medicinal chemistry, DMPK, and compound management, leveraging its collection of over 1.5 million managed compounds. With a proven track record of executing over 150 assays and 30+ hit-to-lead campaigns, BioAscent accelerates external client R&D programs, particularly in challenging areas like CNS and GPCR drug discovery. Its strategic collaborations with academia and biotech firms underscore its role as a key enabler in the early-stage drug discovery ecosystem.

Integrated drug discovery platform combining discovery biology (assay development, HTS, biophysics), medicinal/synthetic chemistry, in silico discovery, DMPK, and compound management. Specialized in GPCR and CNS drug discovery, with in-house diversity, fragment, and chemogenomic libraries.

Competes in the fragmented drug discovery CRO market against large players like Charles River, Evotec, and Eurofins, as well as numerous specialized boutiques. Differentiation is based on integrated service offering, specific expertise in challenging target classes (GPCRs, CNS), and its large, managed compound collection. Collaborations with academia and tech providers help maintain a competitive edge.